Skip to content
BioCentury This Week cover art

All episodes

BioCentury This Week, 407 episodes. Page 4 of 5.

#
Title
301

Ep. 104 - Biotech Shows Support for Ukraine, Plus Latest Intellia Data

302

Ep. 103 - Califf’s Priorities for Second Stint as FDA Commissioner

303

Ep. 102 - What FDA's Tyvyt Precedent Means for China; plus Translational Trendspotting

304

Ep. 101 - Of Biotech Bears, Pazdur & PDUFA

305

Ep. 100 - Capital markets check in; plus Belgium’s prodigal son returns

306

Ep. 99 - Introducing The BioCentury Show, Plus Califf, COVID and GSK

307

Ep. 98 - Bargain Hunting in a Rocky Market, plus Advantage, CMS

308

Ep. 97 - Buysiders' Picks, plus JPM22 roundup

309

Ep. 96 - Aduhelm, Pazdur, Pharma Digital & '21 Wrap

310

Ep. 95 - ASH's New Targets, Avistone & Washington Update

311

Ep. 94 - Woodcock's To-Do List, Maraganore's Takeaways & the Distillery

312

Ep. 93 - Omicron's Open Questions, Plus the Business Case for Ultra-rare Diseases

313

Ep. 92 - Biogen’s R&D decision, previewing TIGIT & China Summit highlights

314

Ep. 91 - China Summit Highlights: Day 2

315

Ep. 90 - China Summit Highlights: Day 1

316

Ep. 89 - Califf's Passions, RWE in China & LSP Rising

317

Ep. 88 - China Summit Preview: The Bridge to Innovation

318

Ep. 87 - Digesting Drug Pricing, Plus Access in ALS

319

Ep. 86 - Woodcock's Legacy, Plus Frazier, Bain & the Distillery

320

Ep. 85 - What's Next for CRISPR & Gene Therapy, Plus China Summit Preview

321

Ep. 84 - Why Gene Therapy's Bad Year Is a Speed Bump, Not a Dead End

322

Ep. 83 - Assessing Biogen’s ALS Miss, Plus Califf on Deck

323

Ep. 82 - 4Q Markets Preview, Plus the Future of NIH

324

Ep. 81 - Merck & the State of M&A, Plus Novartis CEO's Call to Action

325

Ep. 80 - Hong Kong Rising, Plus Varmus' POV & Biden's FDA Choice

326

Ep. 79 - ESMO, Jeito & the Latest from Washington

327

Ep. 78 - Remembering Fred Frank, Lisa Raines, Plus CRISPR, Washington Updates

328

Ep. 77 - Back to School Spotlight & Pressures on FDA

329

Ep 76 Pt. 4 - Modifying Access for Accelerated Approvals

330

Ep 76 Pt. 3 - Delivering the Evidence for Accelerated Approval

331

Ep 76 Pt. 2 - Standards of Evidence for Accelerated Approval

332

Ep 76 Pt. 1 - Accelerated Approval's Big Picture

333

Ep. 75 - Back to School Preview, plus Pfizer Eats Trillium

334

Ep. 74 - Vertex's Road Map & Innovation in MS

335

Ep. 73 - Next Up in COVID with Otello Stampacchia and Umer Raffat

336

Ep. 72 - Modality Matters: M&A Heats Up, Galbraith Maps AZ's BD

337

Ep. 71 - Lessons from China’s Market Turmoil, Plus Distillery on Tap

338

Ep. 70 - Prepping for China’s IP law with Jones Day’s Tony Chen

339

Ep. 69 - Allaying Aduhelm Concerns, Plus Master Protocols, Arvinas-Pfizer

340

Ep. 68 - Drug Pricing Pressure, Plus European Deal Trends

341

Ep. 67 - Aduhelm: a Tangled Plot; Plus, INTREPID Pandemic Planning

342

Ep. 66 - Biotechs hit 3Q with Coolers Full of Cash; plus Distillery on Tap

343

Ep. 65 - Optimism for Intellia's CRISPR Breakthrough, Concerns about Aduhelm

344

Ep. 64 - Amyloid Analysis: Stress Testing FDA's Logic on Surrogate Endpoint

345

Ep. 63 - Woodcock, Noubar and Genmab’s dealmaking: A BioCentury Podcast

346

Ep. 62 - Reflecting on the Implications of Aduhelm's Approval: A BioCentury Podcast

347

Ep. 61 - Dissecting FDA's Aducanumab Decision

348

Ep. 60 - D-Day for Aducanumab: What's at stake

349

Ep. 59 - KRAS to the Future; plus ARPA-H & EGFR

350

Ep. 58 - LAG3 Before You Leap; plus BEE21, G20 Highlights

351

Ep. 57 - Financing Scandinavia; plus IP Waivers, Long Covid & AAV Pays

352

Ep. 56 - FDA’s ODAC Bind; plus NK Cell Engagers and Company Creation in Europe

353

Ep. 55 - German Plays Deliver on Data, plus Accelerated Approval on Trial

354

Ep. 54 - Patient Groups’ Pandemic Pain; plus Voters’ Rights and Synthetic Lethality

355

Ep. 53 - Competence & Continuity at CDER; plus BIO 3.0, AACR and 2Q Preview

356

Ep. 52 - Memories of John Martin, plus AACR's Hot Targets & Bio€quity Europe Preview

357

Ep. 51 - Abernethy & the Obvious at FDA; Plus CEPI & EpimAb

358

Ep. 50 - FTC & the Zombie Pharma Dinosaurs; Plus: RIP José Baselga, NCATS & SPACs

359

Ep. 49 - Vaccine Vexed; Plus Assessing Lilly's Alzheimer's Data & PDUFA Preview

360

Ep. 48 - New Modality Deep Dive; plus Sharpless Speaks & Five Prime Scores

361

Ep. 47 - Whither Woodcock; plus Refresh for German Biotech & Modalities to Market

362

Ep. 46 - Pipeline plays for BMS, Rigel; plus J&J's vaccine panel & access for Africa

363

Ep. 45 - Start-Up Trends, COVID Variants and J&J's Adcomm

364

Ep. 44 - Biotech's IPO blizzard, plus GameStop, Porter Report & Vaccine Guidance

365

Ep. 43 - Europe's Next Act & the Porter Report

366

Ep. 42 - Warp Speed Reflections, Master Protocols & Biden’s COVID Plan

367

Ep. 41 - Biden's Science Team; Plus: Early Cancer Detection

368

Ep. 40 - Investors' Picks & Access to Capital in 2021

369

Ep. 39 - COVID Accountability, Biden's Bidding & Start-up Season

370

Ep. 38 - Crucible of COVID, Ahoy 2021 & Cancer Deal Trends

371

Ep. 37 - 2020's Silver Linings, New Year's Hopes

372

Ep. 36 - Vaccines march forward & CAR Ts move earlier: a BioCentury podcast

373

Ep. 35 - ASH Monday, Biden's Picks & Vaccine Conundrums

374

Ep. 34 - Moderna Moves & Immunocore Breaks Through

375

Ep. 33 - ASH Preview & Long Shot Drug Pricing Rule

376

Ep. 32 - Moderna Times & China's Future

377

Ep. 31 - Pfizer & Biogen: The Good, the bAD and What's Next

378

Ep. 30 - ICER's Influence and Election Effects

379

Ep. 29 - SPACs & Vax

380

Ep. 28 - FDA's Future & China Summit Preview

381

Ep. 27 - CRISPR advances and mega-IPOs: a BioCentury podcast

382

Ep. 26 - Treating Trump & BMS's $13B MyoKardia buy

383

Ep. 25 - Alzheimer Milestones & Vaccine Politics

384

Ep. 24 - Azar's Memo & Biotech's Deals

385

Ep. 23 - $21B Deal by Gilead, None by PhRMA

386

Ep. 22 - Back to School, Behind the Scenes

387

Ep. 21 - FDA’s Credibility on the Line, plus Biotech’s Venture Wave

388

Ep. 20 - Politics & Plasma

389

Ep. 19 - I Want KaNDy, Plus Sputnik V & M&A amid COVID-19

390

Ep. 18 - BIOEquality, Data Sharing and Deals

391

Ep. 17 - Warp Speed, Decentralized Trials & SPACs

392

Ep. 16 - Trump's Ultimatum, RADx & Preclinical IPOs

393

Ep. 15 - Vaccine Hopes, the Shifting Biopharma Workplace & Blueprint's Dx Deal

394

Ep. 14 - Investor Sentiment, HCQ Redux and Attacking AMR

395

Ep. 13 - Nuances of NASH, COVID Vaccines and Real-World Data

396

Ep. 12 - Remdesivir's Price, RWD’s Moment & A Genomics Breakup

397

Ep. 11 - Funding U.K. Biotechs, plus Global Vaccine Access

398

Ep. 10 - EUAs, ACTIV & M&A

399

Ep. 9 - IPOs, Vaccines & BIO's New Leader

400

Ep. 8 - Financing Flurry & Purchasing Pools